Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin was able to get Priority Review for its expanded label of Vascepa to reduce cardiovascular risk for patients with statin-managed LDL-C cholesterol.

Upon Vascepa Expanded Label, The Landscape For Cardiovascular Disease Would Greatly Change

The SNDA for Vascepa was granted a priority review designation.

Amarin: Vascepa Marches Towards An Expanded Label

Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.

Amarin Rises on Priority Review for Vascepa Label Expansion

Axon Enterprise

Royal Gold

If you are looking for interesting investment opportunities, then this diverse trio should be on your watchlist right now.

3 Top Mid-Cap Stocks to Buy Right Now: Amarin, Axon Enterprise & Royal Gold

Cypress Semiconductor

HEICO

These stocks managed to overcome a big swoon in the market.

Why Cypress Semiconductor, Amarin, and Heico Jumped Today

The FDA plans to review Vascep within six months instead of the usual 10, with a decision on approval expected sometime in late September.

FDA agrees to fast-track review of Amarin's prescription strength fish oil pill for heart patients

Amarin stock jumped Wednesday after the Food and Drug Administration granted the biotech company's high cholesterol treatment priority review in preventing cardiovascular trouble.

This Biotech Stock Rocketed Near A Buy Point On Speedy Drug Review

The FDA agreed to expedite a key regulatory decision for Vascepa.

Here's Why Amarin Soared Today

Shares of mid-cap biotech Amarin Corporation plc are advancing solidly in pre-market trading Wednesday.

Amarin's Cardiovascular Fish Oil Pill May Hit Market Sooner: FDA Accords Priority Review Designation

BioMarin Pharmaceutical

Cellectar BioSciences

GW Pharmaceuticals

Sanofi

The biotechnology space is an exciting one with incredible potential for investors.

5 Biotech Stocks With Near-Term Catalysts Ahead

Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Amarin (AMRN) Stock

Strong first-quarter numbers couldn't reverse Amarin's recent slide. Here's why.

Why Amarin's Stock Sank on Strong First-Quarter Results

The small biotech continued to enjoy strong sales for Vascepa. But even better news could be on the way.

Here's What You Need to Know From Amarin's Q1 Earnings Update

Amarin's (AMRN) CEO John Thero on Q1 2019 Results - Earnings Call Transcript

Amarin (AMRN) surpasses estimates for earnings and sales in the first quarter of 2019.

Amarin (AMRN) Beats Estimates for Earnings & Revenues in Q1

Shares of Amarin are trading in a relatively narrow range since the start of 2019.

Why Amarin Is Stuck In A Trading Range

Amgen

Exact Sciences

Merck

If you thought Monday was exciting, wait until you see what's on the slate for the rest of the week.

4 More Healthcare Earnings Reports to Watch This Week

Amarin's stock is stuck in a rut, but this quiet period might turn out to be a great buying opportunity.

Is Amarin (AMRN) a Buy?

Vascepa's sales growth was already strong enough to make the $350 million guidance look easily beatable.

Amarin: Update To Standards Of Medical Care In Diabetes Gives Vascepa A Boost

Amarin Corporation plc shares have been on a strong upward trend since late Wednesday, with the buying momentum continuing into Thursday's session.

Amarin Rallies After Diabetes Association Adds Fish Oil Capsule To Standards of Care List

Amarin Corporation presented data for its cardiovascular outcome study of its prescription Vascepa (icosapent ethyl), the REDUCE-IT study.

Amarin Reports Encouraging Data, Vascepa Shows 30% Reduction In Total Cardiovascular Events In REDUCE-IT Study

AstraZeneca

Jazz Pharmaceuticals

Ligand Pharmaceuticals

Leap Therapeutics

Lexicon Pharmaceuticals

PhaseBio Pharmaceuticals Inc

Roche Holding AG

SAGE Therapeutics

Strongbridge Biopharma

Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support.

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

This high-flying biotech stock is taking a breather. Time to buy?

Is Amarin a No-Brainer Stock to Buy on the Dip?

On February 27, Amarin Corporation (AMRN) reported its fourth-quarter and full-year 2018 financial results and operations update.

Is Amarin's Prescription Growth Going To Stall, Or Is It Just Getting Started?

The entire share-price increase was compressed into the last week of February

News for Amarin Corporation Plc Stock (AMRN)